Literature DB >> 3494844

Interstitial lung disease in dermatomyositis: clinicopathological study.

H Takizawa, J Shiga, Y Moroi, S Miyachi, M Nishiwaki, T Miyamoto.   

Abstract

We studied 14 cases of polymyositis-dermatomyositis (PM-DM) and found roentgenographic evidence of interstitial lung disease in 9 patients with DM (64.3%). Serum anti-Jo-1 antibody was demonstrated in only one case. Histologically, interstitial pneumonitis and fibrosis were noted in all cases. Deposition of immunoglobulins along the alveolar interstitium was not found in any case. Response to corticosteroid therapy was poor, and 6 cases (67%) succumbed to respiratory failure and died. We conclude that interstitial lung disease in DM occurs more frequently than previously reported and may be an important prognostic factor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494844

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

Review 1.  Organising pneumonia.

Authors:  J F Cordier
Journal:  Thorax       Date:  2000-04       Impact factor: 9.139

2.  Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease.

Authors:  Thomas J Richards; Aaron Eggebeen; Kevin Gibson; Samuel Yousem; Carl Fuhrman; Bernadette R Gochuico; Noreen Fertig; Chester V Oddis; Naftali Kaminski; Ivan O Rosas; Dana P Ascherman
Journal:  Arthritis Rheum       Date:  2009-07

3.  Cyclosporin for dermatomyositis.

Authors:  S Levi; H J Hodgson
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

4.  Autoantibodies in juvenile dermatomyositis.

Authors:  E Martínez-Cordero; E Martínez-Miranda; D E Aguilar León
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

Review 5.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

6.  Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study.

Authors:  Sangmee Bae; Christina Charles-Schoeman
Journal:  Clin Rheumatol       Date:  2018-07-03       Impact factor: 2.980

7.  Report of a Patient With Anti-Jo-1 Syndrome With Loss of Consciousness.

Authors:  Chun Chen; Yu-Jang Su; Chiong-Hee Wong
Journal:  J Acute Med       Date:  2022-06-01

8.  Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis.

Authors:  Yuzo Suzuki; Hiroshi Hayakawa; Seiichi Miwa; Masahiro Shirai; Masato Fujii; Hitoshi Gemma; Takafumi Suda; Kingo Chida
Journal:  Lung       Date:  2009-04-22       Impact factor: 2.584

9.  Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis.

Authors:  K Kurasawa; Y Nawata; K Takabayashi; K Kumano; Y Kita; Y Takiguchi; T Kuriyama; M Sueishi; Y Saito; I Iwamoto
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 10.  Role of Microbial Agents in Pulmonary Fibrosis
.

Authors:  Ozioma S Chioma; Wonder P Drake
Journal:  Yale J Biol Med       Date:  2017-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.